Edition:
United States

People: Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

3.75USD
12:40pm EDT
Change (% chg)

$-0.02 (-0.53%)
Prev Close
$3.77
Open
$3.80
Day's High
$3.85
Day's Low
$3.72
Volume
1,683,626
Avg. Vol
6,332,574
52-wk High
$7.15
52-wk Low
$3.35

Adams, Thomas 

Dr. Thomas H. Adams, Jr. Ph.D. is an Independent Director of the Company. He served as a director of our Company since July 2008. Since June 2005, Dr. Adams has served as a director of IRIS International, Inc., a diagnostics company, and as Chief Technology Officer of IRIS from April 2006 until November 2012 when it was acquired by Danaher Corporation. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006, when Leucadia was acquired by IRIS. In 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Before founding Gen-Probe, Dr. Adams held management positions at Technicon Instruments and the Hyland Division of Baxter Travenol. He has significant public-company experience serving as a director of Biosite Diagnostics, Inc., a publicly held medical research firm, from 1989 to 1998 and as a director of Invitrogen, a publicly held company that develops, manufactures and markets research tools and products, from 2000 to 2002. Dr. Adams currently serves as a director of Xifin, Inc., a private lab billing company and Interim Chief Executive Officer and Chairman of the Board of Trovagene, Inc. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside. Dr. Adams’s executive leadership, particularly in the healthcare field, and the extensive healthcare expertise he has developed qualifies Dr. Adams to serve as a director of our company.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gary Jacob

4,211,680

Gary Gemignani

--

Marino Garcia

--

Patrick Griffin

1,195,750

Troy Hamilton

1,362,920

Bernard Denoyer

707,434
As Of  30 Dec 2015